<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Deficiency of adenosine deaminase 2 (DADA2)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Deficiency of adenosine deaminase 2 (DADA2)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Deficiency of adenosine deaminase 2 (DADA2)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pui Y Lee, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Nigrovic, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H934009515"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Deficiency of adenosine deaminase 2 (DADA2) is a rare, recessively inherited autoinflammatory disease characterized by systemic inflammation, vasculitis, early-onset stroke, cytopenias, and immunodeficiency. Initially recognized as a monogenic form of systemic vasculitis that resembles polyarteritis nodosa (PAN), DADA2 is caused by biallelic pathogenic variants in the adenosine deaminase 2 gene (<em>ADA2</em>; formerly known as <em>CECR1</em>) on chromosome 22q11 [<a href="#rid1">1,2</a>]. The clinical spectrum of DADA2 is broad, and manifestations can vary even among family members with the same genotype [<a href="#rid3">3,4</a>]. DADA2 can also present as bone marrow failure and immunodeficiency, with or without features of inflammation and vasculitis.</p><p>Additional topics cover other specific autoinflammatory diseases:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5956.html" rel="external">"Hyperimmunoglobulin D syndrome: Pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/5954.html" rel="external">"Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms"</a>.)</p><p></p><p>A general discussion of autoinflammatory diseases is available separately, as are topics on classification and genetic diagnosis of inborn errors of immunity:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117758.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Classification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116805.html" rel="external">"Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H2178766978"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>More than 300 cases of DADA2 have been published in the literature since the first description of this syndrome in 2014. The carrier frequency for deleterious <em>ADA2</em> variants is estimated to be 1 in 236 persons worldwide based on functional annotation of population variants in Genome Aggregate Database (gnomAD) [<a href="#rid5">5</a>]. Accordingly, disease prevalence is expected to be approximately 1 in 222,000 persons. Carrier frequency and disease prevalence vary significantly among different populations. (See <a class="local">'Genetics'</a> below.)</p><p>Among 48 European children with early-onset vasculitis, 15 (31 percent) were found to have DADA2 [<a href="#rid6">6</a>]. Screening of adult patients with polyarteritis nodosa (PAN) found that 4 out of 108 cases (3.4 percent) possessed biallelic pathogenic <em>ADA2</em> variants, and several others carried a single pathogenic variant [<a href="#rid7">7</a>]. By contrast, DADA2 was not found among 1107 patients with granulomatosis with polyangiitis or microscopic polyangiitis [<a href="#rid7">7</a>]. (See <a class="local">'Vasculitis'</a> below.)</p><p>In a genomic survey of patients with Diamond-Blackfan anemia (DBA), 9 out of 472 cases (2 percent) possessed biallelic pathogenic <em>ADA2</em> variants in the absence of the ribosomal protein gene mutations associated with DBA [<a href="#rid8">8</a>]. (See <a class="local">'Bone marrow failure'</a> below.)</p><p class="headingAnchor" id="H2944338676"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>DADA2 is recessively inherited, and approximately half of cases are caused by compound heterozygous pathogenic variants [<a href="#rid9">9</a>]. These pathogenic variants have been described in all exons and functional domains of ADA2. However, as with most monogenic autoinflammatory diseases, DADA2 exhibits incomplete penetrance (not all patients with mutations have clinical disease) [<a href="#rid10">10,11</a>].</p><p>Missense <em>ADA2</em> variants account for most disease-associated mutations, especially in cases with the vasculitis phenotype. Loss-of-function variants (nonsense and insertions/deletions with frameshift) are more commonly found in patients with severe hematologic compromise due to bone marrow failure. Studies characterizing DADA2 variants in vitro reveal a gradient of residual function, with complete or near absence of functional protein correlating with hematologic disease (often without vasculitis), while retention of some functional protein correlates with risk for stroke and other vasculitic manifestations [<a href="#rid12">12,13</a>]. This genotype-phenotype correlation has important therapeutic implications because tumor necrosis factor (TNF) inhibitors effectively ameliorate the vasculitis phenotype but have little efficacy in DADA2 patients with bone marrow failure. (See <a class="local">'Vasculitis'</a> below and <a class="local">'Bone marrow failure'</a> below and <a class="local">'Treatment'</a> below.)</p><p>The most common pathogenic variant associated with DADA2, p.Gly47Arg (G47R), is found in the majority of patients from Turkey, Israel, and South Asia. Persons with homozygous G47R mutations typically exhibit the vasculitis phenotype that resembles polyarteritis nodosa (PAN) [<a href="#rid14">14,15</a>]. In Europeans, the most common DADA2-associated variant is p.Arg169Gln (R169Q). This variant likely originated in Northern Europe, with the highest carrier frequency (1 in 160) found in Finland. Patients with homozygous R169Q display variable features of vasculitis, severe hematologic defects, and/or immunodeficiency [<a href="#rid4">4,16</a>].</p><p class="headingAnchor" id="H695729197"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>ADA2 is one of two enzymes that catalyze conversion of adenosine to inosine. The major intracellular enzyme responsible for this function is adenosine deaminase 1 (ADA1). Deficiency of ADA1 leads to an accumulation of toxic metabolic products that impair lymphocyte viability and presents as T-negative, B-negative, natural killer (NK) negative severe combined immunodeficiency (SCID) (see  <a class="medical medical_review" href="/z/d/html/3907.html" rel="external">"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis"</a>). By contrast, ADA2 is an extracellular protein produced preferentially by monocytes, macrophages, and dendritic cells, although ADA1 may also be present extracellularly due to cell turnover and lysis of erythrocytes [<a href="#rid17">17,18</a>].</p><p>It is unknown whether DADA2 reflects loss of enzymatic activity or another mechanism, in particular because the adenosine deaminase activity of ADA2 is 100-fold weaker than that of ADA1 due to lower affinity for adenosine [<a href="#rid17">17</a>]. The accumulation of toxic metabolites deoxyadenosine and deoxyadenosine triphosphate seen in ADA-SCID is not observed in DADA2, suggesting nonredundant physiologic roles of ADA1 and ADA2.</p><p>ADA2 promotes T cell proliferation independent of its enzymatic activity and also augments the differentiation of monocytes to macrophages [<a href="#rid19">19,20</a>]. Correspondingly, monocytes from DADA2 patients exhibit impaired expansion into immunomodulatory M2 macrophages [<a href="#rid1">1</a>]. These observations suggest disease driven by an intrinsic defect in monocyte/macrophage biology. Alternately, inflammation may arise through failure to degrade extracellular adenosine at the tissue level, triggering neutrophils to release immunostimulatory neutrophil extracellular traps (NETs) that subsequently stimulate macrophages to produce tumor necrosis factor (TNF) [<a href="#rid21">21</a>].</p><p>TNF has a critical role in driving the systemic inflammation and vasculitis in DADA2, as reflected in the efficacy of TNF inhibition in the prevention of recurrent stroke [<a href="#rid22">22</a>]. Type I interferons also may play a role, as suggested by the detection of an interferon signature by gene expression profiling of peripheral blood [<a href="#rid23">23-25</a>]. In vitro studies suggest that ADA2 could serve as a direct regulator of interferon production by modulating adenosine levels or as a lysosomal nuclease that regulates interferon production induced by endogenous nucleic acids [<a href="#rid26">26,27</a>]. However, the clinical phenotype of DADA2 is largely distinct from that of type I interferonopathies (see  <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">"Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"</a>). It remains to be seen whether excess interferon production is observed across the different phenotypes of DADA2 and whether these antiviral cytokines contribute to the pathophysiology of DADA2.</p><p class="headingAnchor" id="H3440548394"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3933990251"><span class="h2">Phenotypes</span><span class="headingEndMark"> — </span>DADA2 was initially identified as a monogenic form of systemic vasculitis that affects medium- and small-sized vessels  (<a class="graphic graphic_figure graphicRef130144" href="/z/d/graphic/130144.html" rel="external">figure 1</a>). This vasculitis phenotype accounts for most cases in the literature and remains the more common presentation of DADA2. A second phenotype characterized by bone marrow failure was recognized later. While the overlapping feature of vasculitis and cytopenia are seen in some patients, these two phenotypes differ in genotype (see <a class="local">'Genetics'</a> above) and treatment response (see <a class="local">'Treatment'</a> below). Immunodeficiency is another feature of DADA2, but whether it constitutes a distinct clinical phenotype is unclear [<a href="#rid28">28,29</a>]. Impaired humoral immunity and recurrent infection are seen in DADA2 with both vasculitis and hematologic phenotypes [<a href="#rid1">1,12</a>].</p><p class="headingAnchor" id="H2179224156"><span class="h2">Age at presentation</span><span class="headingEndMark"> — </span>Most patients exhibit first disease manifestations during childhood, with an average age of onset of five to seven years; approximately 25 percent of patients are diagnosed before one year of age and 77 percent by age 10 years [<a href="#rid30">30,31</a>]. Patients with DADA2 who have pure red cell aplasia and bone marrow failure tend to present during early infancy, whereas delayed presentation is common in patients with vasculitis and systemic inflammation [<a href="#rid12">12</a>]. With growing awareness of DADA2 and greater availability of diagnostic tests, new cases are increasingly recognized in adults, with diagnosis as late as the seventh decade of life [<a href="#rid14">14,32,33</a>]. It is not clear what factors precipitate disease onset [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H1148870047"><span class="h2">Vasculitis</span><span class="headingEndMark"> — </span>Vessel wall inflammation leading to stenosis, aneurysm formation, and perforation drive the organ-specific manifestations of DADA2  (<a class="graphic graphic_figure graphicRef130144" href="/z/d/graphic/130144.html" rel="external">figure 1</a>). Vasculitis may affect the skin, cranial nerves, peripheral nerves, digits, kidneys, intestine, and even testes, with pathologic features that are indistinguishable from polyarteritis nodosa (PAN) [<a href="#rid1">1,2,6,34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic</strong> – Inflammation of blood vessels most characteristically involves the central nervous system (CNS), resulting in recurrent strokes that are either ischemic or hemorrhagic, often beginning in early childhood [<a href="#rid1">1</a>]. Stroke is reported in approximately one-third of DADA2 patients and may be the initial presenting feature [<a href="#rid30">30,31,35</a>]. The risk for stroke appears to be greater in patients diagnosed with DADA2 during childhood rather than adulthood [<a href="#rid36">36</a>]. The incidence of cerebral vascular events is likely underestimated due to silent infarcts and mild cases with transient symptoms (ie, transient ischemic attack). Neuropathy of cranial and peripheral nerves is common and distinguishes DADA2 from childhood PAN [<a href="#rid6">6</a>]. Neurosensory hearing loss, vision loss, central retinal artery occlusion, optic nerve atrophy, and uveitis have all been described in patients with DADA2 [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – Common skin manifestations include livedo racemosa (considered to reflect vasculopathy), subcutaneous nodules, and erythematous papules  (<a class="graphic graphic_picture graphicRef134587" href="/z/d/graphic/134587.html" rel="external">picture 1</a>); ulcerations and skin necrosis are seen in some patients. Severe skin vasculitis is more common in adults with DADA2 [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal</strong> – Musculoskeletal complications are observed in approximately half of patients, and arthritis can affect small and large joints. A plethora of visceral organ involvement including infarction of bowels, kidneys, spleen and pancreas; upper and lower gastrointestinal tract bleeding; diffuse alveolar hemorrhage; and cardiac inflammation have been reported in DADA2  (<a class="graphic graphic_diagnosticimage graphicRef134298" href="/z/d/graphic/134298.html" rel="external">image 1</a>).</p><p></p><p class="headingAnchor" id="H541171826"><span class="h2">Systemic inflammation</span><span class="headingEndMark"> — </span>Features of systemic inflammation are common in patients with the DADA2 vasculitis phenotype and sometimes appear before localized manifestations of vascular inflammation. Patients exhibit constitutive symptoms, lymphadenopathy, elevated transaminases, and elevation of inflammatory markers, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Children may exhibit poor growth. Presentation with fever, lymphadenopathy, and hepatosplenomegaly can resemble autoimmune lymphoproliferative syndrome (ALPS), multicentric Castleman disease, or other autoinflammatory syndromes [<a href="#rid37">37-39</a>]. Macrophage activation syndrome has also been reported in rare cases [<a href="#rid3">3,12</a>]. (See  <a class="medical medical_review" href="/z/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/117312.html" rel="external">"HHV-8-negative/idiopathic multicentric Castleman disease"</a> and  <a class="medical medical_review" href="/z/d/html/13512.html" rel="external">"Systemic juvenile idiopathic arthritis: Course, prognosis, and complications", section on 'Macrophage activation syndrome'</a>.)</p><p class="headingAnchor" id="H3190928183"><span class="h2">Bone marrow failure</span><span class="headingEndMark"> — </span>Patients may exhibit anemia, neutropenia, and lymphopenia, in some cases with transfusion-dependent pure red cell aplasia resembling Diamond-Blackfan anemia (DBA) [<a href="#rid40">40-43</a>]. Patients with pure red cell aplasia or bone marrow failure represent a minority of patients with DADA2 and typically present during early childhood. Autoimmune cytopenias are less common, but Evans syndrome and idiopathic thrombocytopenic purpura have been reported as presenting features of DADA2 [<a href="#rid40">40,44</a>]. Bone marrow biopsy of DADA2 patients typically shows diminished erythroid, myeloid, and/or lymphoid development. Lymphoid aggregates in the bone marrow are often seen, but their significance is unclear [<a href="#rid42">42,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Diamond-Blackfan anemia'</a>.)</p><p class="headingAnchor" id="H815154954"><span class="h2">Immunodeficiency</span><span class="headingEndMark"> — </span>Approximately half of patients with DADA2 exhibit low levels of immunoglobulin, including immunoglobulin M (IgM), immunoglobulin A (IgA), and immunoglobulin G (IgG) [<a href="#rid1">1,12,29</a>]. In some cases, progressive decline in immunoglobulins is reminiscent of common variable immunodeficiency (CVID) [<a href="#rid29">29</a>]. Upper and lower respiratory infections are the most common manifestations of immunodeficiency in patients with DADA2, although chronic Epstein-Barr virus infection and recurrent cutaneous herpes (not usually associated with isolated humoral immunodeficiency) have been documented [<a href="#rid29">29,46,47</a>]. Infection with opportunistic pathogens such as fungi and mycobacteria also have been reported, although some of these cases are confounded by concurrent neutropenia and lymphopenia in the setting of bone marrow failure [<a href="#rid12">12,40,45</a>]. In some patients, recurrent infection is the sole presenting feature [<a href="#rid28">28,29</a>]. Immunologic characterization reveals defective B cell development in the bone marrow at the pro-B to pre-B cell stage as well as impaired memory B cell class switching [<a href="#rid29">29,48,49</a>]. Expanded immunophenotyping further shows impaired differentiation of memory T cells with features of accelerated exhaustion/senescence, impaired survival, and granzyme production [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1941256600"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H71011814"><span class="h2">Approach</span><span class="headingEndMark"> — </span>The diagnosis of DADA2 should be suspected in children and young adults who present with polyarteritis nodosa (PAN) like vasculitis and ischemic or hemorrhagic stroke, especially in the presence of livedo, systemic inflammation, cytopenias, and hypogammaglobulinemia (see <a class="local">'Clinical manifestations'</a> above). It is confirmed by genetic studies that identify biallelic deleterious <em>ADA2 </em>variants or by a biochemical assay that demonstrates near-absent levels of ADA2 activity in the plasma or serum. The choice of testing for DADA2 is based on urgency and availability. Our practice is to measure plasma ADA2 activity to rule in or rule out DADA2 and then to arrange genetic studies to confirm the diagnosis. An alternate approach is to screen with genetic panels containing multiple immune dysregulatory inborn errors of metabolism genes. Given the recessive pattern of inheritance and incomplete penetrance, as well as reports of symptomatic carriers, we screen all siblings of patients with confirmed DADA2 as well as any other family members with clinical features of the disease.</p><p class="headingAnchor" id="H417444927"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>The <em>ADA2</em> gene is included in many commercially available sequencing panels for periodic fever syndromes and primary immunodeficiencies. Most disease-associated <em>ADA2</em> variants are captured by targeted next-generation sequencing or by whole-exome sequencing. However, large deletions and complex chromosomal rearrangements can be missed by standard sequencing technology, and dedicated studies to analyze copy number variants such as multiplex ligation-dependent probe amplification may be necessary to resolve these cases [<a href="#rid11">11,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/16647.html" rel="external">"Genomic disorders: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/116805.html" rel="external">"Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H1222095522"><span class="h2">Biochemical assays</span><span class="headingEndMark"> — </span>Measurement of ADA2 enzymatic activity can rapidly diagnose DADA2 on the basis of absent or near-absent activity in patient serum or plasma. ADA2 enzyme testing is useful to identify patients with DADA2 who do not have identifiable <em>ADA2</em> variants, who have one deleterious variant, or who carry variants of unknown significance. Spectrophotometric assays that detect the conversion of adenosine to inosine and mass spectrometry quantification of inosine (and the downstream product hypoxanthine) have been described [<a href="#rid51">51,52</a>]. These assays require the use of a specific ADA1 inhibitor, typically erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), to distinguish the enzymatic activity of ADA2 from that of the more potent enzyme. Patients with DADA2 exhibit minimal or no residual activity, while persons heterozygous for a deleterious variant exhibit intermediate levels of enzymatic activity between patients with DADA2 and controls [<a href="#rid1">1,9,17</a>]. These tests are not available but are routinely performed as a service by several research laboratories.</p><p class="headingAnchor" id="H4253293934"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H2345966757"><span class="h2">Stroke or peripheral vasculitis</span><span class="headingEndMark"> — </span>DADA2 presenting as stroke or peripheral vasculitis engages a differential diagnosis that includes other forms of vasculitis such as Sneddon syndrome and polyarteritis nodosa (PAN):</p><p class="bulletIndent1"><span class="glyph">●</span>Sneddon syndrome is a rare thrombotic vasculopathy characterized by ischemic strokes and livedo racemosa that affect females between 20 to 40 years of age [<a href="#rid53">53</a>]. Several cases of DADA2 were previously diagnosed as Sneddon syndrome; low IgM levels favor the diagnosis of DADA2 [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with classic PAN, patients with DADA2 typically are younger (mean age of onset four to five years versus nine years of age), more frequently have neurologic involvement, and commonly have ancillary manifestations of DADA2 such as hypogammaglobulinemia and/or cytopenias [<a href="#rid6">6,9,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification", section on 'Polyarteritis nodosa'</a> and  <a class="medical medical_review" href="/z/d/html/6430.html" rel="external">"Vasculitis in children: Evaluation overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some cases have striking resemblance to Behçet syndrome, and monoallelic <em>ADA2 </em>variants have been reported in a cohort of patients with Behçet disease [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although autoimmunity is generally uncommon in DADA2, manifestations of antiphospholipid syndrome and systemic lupus erythematous including the characteristic interferon signature seen in lupus have been described [<a href="#rid24">24,57</a>].</p><p></p><p class="headingAnchor" id="H3178301168"><span class="h2">Pure red cell aplasia</span><span class="headingEndMark"> — </span>DADA2 presenting as pure red cell aplasia can resemble Diamond-Blackfan anemia (DBA) [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Diamond-Blackfan anemia'</a>.)</p><p class="headingAnchor" id="H3016636159"><span class="h2">Immunodeficiency</span><span class="headingEndMark"> — </span>The humoral immunodeficiency manifesting as variable hypogammaglobulinemia and impaired B cell switch response can resemble common variable immunodeficiency (CVID). In one patient with severe bone marrow failure and opportunistic infection, GATA binding protein 2 (GATA2) deficiency was suspected before the pathogenic variants in <em>ADA2</em> were found [<a href="#rid45">45</a>]. Patients with CVID have low IgG and one other low immunoglobulin (A or M), by definition, whereas patients with GATA2 have a natural killer (NK) cell abnormality characterized by near absence of CD56bright cells. (See  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a> and  <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'GATA2 deficiency (MonoMAC syndrome)'</a>.)</p><p class="headingAnchor" id="H4033510873"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3972079232"><span class="h2">Phenotype-based treatment</span><span class="headingEndMark"> — </span>Disease phenotype is an important consideration for the treatment of DADA2. Tumor necrosis factor (TNF) inhibition is associated with lower risk of stroke and decreased inflammatory manifestations in patients with vasculitis but does not appear to be effective in patients with bone marrow failure.</p><p class="headingAnchor" id="H2264790500"><span class="h2">Vasculitis and systemic inflammation</span><span class="headingEndMark"> — </span>For patients with DADA2 who have vasculitis and/or systemic inflammation, we suggest treatment with TNF inhibitors. Clinical improvement has been reported with the use of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, as well as biosimilars [<a href="#rid1">1,6,14,22</a>]. Observational data show that the use of TNF inhibitors is associated with a significantly lower risk for additional strokes and decreased inflammatory burden of the disease [<a href="#rid14">14,22,58</a>]. We continue treatment with TNF inhibitors indefinitely. At least one death has occurred due to gastrointestinal hemorrhage several months after discontinuation of TNF inhibitors [<a href="#rid14">14</a>].</p><p>The efficacy of TNF inhibition is illustrated in these example:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series from the United States, 15 patients with DADA2 and a history of strokes were begun on TNF inhibitor therapy with <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> (0.8 to 1.2 mg per kg body weight, maximum of 50 mg weekly), <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> (40 mg every one to two weeks), <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> (4 to 5 mg/kg every six weeks), or <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> (50 mg weekly). In the 2077 patient-months before initiation of treatment, patients had 55 strokes. In 733 patient-months on therapy, no further strokes were observed [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series from the United Kingdom, 27 patients received anti-TNF treatment for a median of 32 months. The median event rate of central nervous system (CNS) and non-CNS ischemic events before anti-TNF treatment was 2.37 per 100 patient-months compared with 0.00 per 100 patient-months posttreatment. General improvement of systemic vasculitis was reflected by a reduction in Pediatric Vasculitis Activity Score (PVAS), with a median score of 20/63 pretreatment versus 2/63 posttreatment [<a href="#rid58">58</a>].</p><p></p><p>Glucocorticoids, disease-modifying antirheumatic drugs, and other biologic agents such as <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (monoclonal interleukin [IL] 6 receptor antagonist) may partially ameliorate systemic inflammation, but these agents are less effective in preventing strokes [<a href="#rid59">59,60</a>]. We typically avoid anticoagulation in DADA2 patients because of concerns that it may precipitate or worsen hemorrhagic stroke.</p><p class="headingAnchor" id="H3095034309"><span class="h2">Asymptomatic or no vasculitis</span><span class="headingEndMark"> — </span>Whether patients discovered to have DADA2 but who have not yet had stroke or other symptoms of vasculitis (eg, discovered by screening of family members) should be treated with TNF inhibitors remains a difficult dilemma. We suggest treating all such patients, even if asymptomatic, because of the potentially devastating and even life-threatening consequences of a first cerebrovascular event. (See <a class="local">'Vasculitis and systemic inflammation'</a> above.)</p><p class="headingAnchor" id="H3150540658"><span class="h2">Symptomatic carriers</span><span class="headingEndMark"> — </span>Some persons present with features of DADA2 but are found to have only a single deleterious <em>ADA2</em> variant and an intermediate level of <em>ADA2</em> enzymatic activity [<a href="#rid6">6,61</a>]. Periodic fever, oral ulcers, skin rash, arthritis, and systemic inflammation have been reported in these symptomatic carriers. Optimal management of heterozygous ADA2 deficiency is uncertain due to the lack of systematic studies. The decision may be influenced by the severity of symptoms in relatives with the same pathogenic variant as well as the preference of the patient/caregivers. In these cases, we seek to balance the active disease features and risk of future disease-related clinical events with the risk and cost of indefinite immunosuppression.</p><p class="headingAnchor" id="H3280506562"><span class="h2">Bone marrow failure and immunodeficiency</span><span class="headingEndMark"> — </span>For patients with DADA2 who have treatment-refractory bone marrow failure, we suggest hematopoietic cell transplantation (HCT) rather than TNF inhibitors and supportive care. TNF inhibitors are generally ineffective for severe hematologic manifestation of DADA2 but may ameliorate concurrent features of inflammation in some patients with bone marrow failure [<a href="#rid12">12,15,58</a>]. In addition, the use of TNF inhibitors in patients with bone marrow failure syndrome and/or immunodeficiency may further increase the risk for infection. Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a>, granulocyte colony-stimulating factor (G-CSF), glucocorticoids, and other immunosuppressive agents also have proven largely ineffective for severe hematologic manifestations. Fresh-frozen plasma contains ADA2, but sustained treatment is not feasible given the short half-life of the protein [<a href="#rid22">22</a>]. Restoration of ADA2 production by HCT is potentially curative for patients, and reduced-intensity conditioning appears to be effective [<a href="#rid16">16,62</a>]. In a cohort of 14 patients that underwent HCT, all patients were alive and well, hematologic and inflammatory features of the disease all showed significant improvement, and no new vascular events were reported during a median follow-up of 18 months [<a href="#rid16">16</a>]. In a series of 30 DADA2 patients, HCT corrected the hematologic phenotype in all patients, although one patient died from infection, six required a second HCT due to graft failure, and six patients developed graft-versus-host disease by one year after transplant [<a href="#rid63">63</a>]. Gene therapy and enzyme replacement therapy are promising options that are undergoing preclinical evaluation.</p><p class="headingAnchor" id="H324487268"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>DADA2 carries an overall mortality rate of approximately 8 percent among known cases [<a href="#rid12">12,64</a>]. The risk may be higher in patients with the bone marrow failure phenotype, of whom half died from infection.</p><p class="headingAnchor" id="H1509403336"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Deficiency of adenosine deaminase 2 (DADA2) should be suspected in children and young adults who present with polyarteritis nodosa (PAN) like vasculitis and ischemic or hemorrhagic stroke, especially in the presence of livedo, systemic inflammation, cytopenias, and/or hypogammaglobulinemia. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of DADA2 is confirmed by identification of biallelic deleterious <em>ADA2</em> variants or by near-absent ADA2 enzymatic activity in the peripheral blood. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for DADA2 presenting as stroke or peripheral vasculitis includes other forms of vasculitis such as Sneddon syndrome and PAN. DADA2 presenting as pure red cell aplasia can resemble Diamond-Blackfan anemia (DBA). Immunodeficiency in DADA2 can mimic common variable immunodeficiency (CVID) or GATA binding protein 2 (GATA2) deficiency. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Disease phenotype is an important consideration for the treatment of DADA2 (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with DADA2 who have vasculitis and/or systemic inflammation, we recommend treatment with tumor necrosis factor (TNF) inhibitors rather than supportive care (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Observational data show that the use of TNF inhibitors, including <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, as well as biosimilars, is associated with a significantly lower risk for additional strokes and decreased inflammatory burden of the disease. (See <a class="local">'Vasculitis and systemic inflammation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with confirmed DADA2 who are asymptomatic or who have not yet had stroke or other symptoms of vasculitis (eg, discovered by screening of family members), we suggest treatment with a TNF inhibitor because of the potentially devastating and even life-threatening consequences of a first cerebrovascular event (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Asymptomatic or no vasculitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with treatment-refractory bone marrow failure, we suggest hematopoietic cell transplantation (HCT) rather than TNF inhibitors and supportive care (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Bone marrow failure and immunodeficiency'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370:911.</a></li><li><a class="nounderline abstract_t">Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370:921.</a></li><li><a class="nounderline abstract_t">Batu ED, Karadag O, Taskiran EZ, et al. A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. J Rheumatol 2015; 42:1532.</a></li><li><a class="nounderline abstract_t">Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 2016; 55:902.</a></li><li><a class="nounderline abstract_t">Jee H, Huang Z, Baxter S, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol 2022; 149:379.</a></li><li><a class="nounderline abstract_t">Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis 2017; 76:1648.</a></li><li><a class="nounderline abstract_t">Schnappauf O, Sampaio Moura N, Aksentijevich I, et al. Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis Rheumatol 2021; 73:512.</a></li><li><a class="nounderline abstract_t">Ulirsch JC, Verboon JM, Kazerounian S, et al. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet 2018; 103:930.</a></li><li><a class="nounderline abstract_t">Huang Z, Li T, Nigrovic PA, Lee PY. Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. Clin Immunol 2020; 215:108411.</a></li><li><a class="nounderline abstract_t">Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases. Arthritis Rheumatol 2016; 68:2314.</a></li><li><a class="nounderline abstract_t">Schnappauf O, Zhou Q, Moura NS, et al. Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance. J Clin Immunol 2020; 40:917.</a></li><li><a class="nounderline abstract_t">Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol 2020; 145:1664.</a></li><li><a class="nounderline abstract_t">Schnappauf O, Ombrello AK, Kastner DL. Deficiency of adenosine deaminase 2: Is it an elephant after all? J Allergy Clin Immunol 2020; 145:1560.</a></li><li><a class="nounderline abstract_t">Sharma A, Naidu G, Sharma V, et al. Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India. Arthritis Rheumatol 2021; 73:276.</a></li><li><a class="nounderline abstract_t">Özen S, Batu ED, Taşkıran EZ, et al. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. J Rheumatol 2020; 47:117.</a></li><li><a class="nounderline abstract_t">Hashem H, Kumar AR, Müller I, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 2017; 130:2682.</a></li><li><a class="nounderline abstract_t">Hashem H, Kelly SJ, Ganson NJ, Hershfield MS. Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders. Curr Rheumatol Rep 2017; 19:70.</a></li><li><a class="nounderline abstract_t">Lee PY, Huang Z, Hershfield MS, Nigrovic PA. Response to: 'Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum' by Gao et al. Ann Rheum Dis 2022; 81:e31.</a></li><li><a class="nounderline abstract_t">Zavialov AV, Engström A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005; 391:51.</a></li><li><a class="nounderline abstract_t">Zavialov AV, Gracia E, Glaichenhaus N, et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 2010; 88:279.</a></li><li><a class="nounderline abstract_t">Carmona-Rivera C, Khaznadar SS, Shwin KW, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood 2019; 134:395.</a></li><li><a class="nounderline abstract_t">Ombrello AK, Qin J, Hoffmann PM, et al. Treatment Strategies for Deficiency of Adenosine Deaminase 2. N Engl J Med 2019; 380:1582.</a></li><li><a class="nounderline abstract_t">Insalaco A, Moneta GM, Pardeo M, et al. Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. J Rheumatol 2019; 46:523.</a></li><li><a class="nounderline abstract_t">Skrabl-Baumgartner A, Plecko B, Schmidt WM, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J 2017; 15:67.</a></li><li><a class="nounderline abstract_t">Nihira H, Izawa K, Ito M, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. J Allergy Clin Immunol 2021; 148:550.</a></li><li><a class="nounderline abstract_t">Dhanwani R, Takahashi M, Mathews IT, et al. Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response. Sci Adv 2020; 6:eaba3688.</a></li><li><a class="nounderline abstract_t">Greinier-Tollersrud OK, Boehler V, Bartok E, et al. ADA2 is a lysosomal DNase regulating the type-I interferon response. bioRxiv 2020; 06:21.162990.</a></li><li><a class="nounderline abstract_t">Schepp J, Bulashevska A, Mannhardt-Laakmann W, et al. Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency. J Clin Immunol 2016; 36:179.</a></li><li><a class="nounderline abstract_t">Schepp J, Proietti M, Frede N, et al. Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood. Arthritis Rheumatol 2017; 69:1689.</a></li><li><a class="nounderline abstract_t">Lee PY. Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2. Front Pediatr 2018; 6:282.</a></li><li><a class="nounderline abstract_t">Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol 2018; 38:569.</a></li><li><a class="nounderline abstract_t">Bourgeois G, Richard M, Danset M, et al. Deficiency of adenosine deaminase 2 diagnosed at 65 years of age. Lancet 2021; 397:913.</a></li><li><a class="nounderline abstract_t">Trotta L, Martelius T, Siitonen T, et al. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol 2018; 141:1534.</a></li><li><a class="nounderline abstract_t">Clarke K, Campbell C, Omoyinmi E, et al. Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2). Pediatr Rheumatol Online J 2019; 17:39.</a></li><li><a class="nounderline abstract_t">Elbracht M, Mull M, Wagner N, et al. Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency. Neuropediatrics 2017; 48:111.</a></li><li><a class="nounderline abstract_t">Fayand A, Chasset F, Boutboul D, et al. DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases. Semin Arthritis Rheum 2021; 51:1170.</a></li><li><a class="nounderline abstract_t">Alsultan A, Basher E, Alqanatish J, et al. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Barzaghi F, Minniti F, Mauro M, et al. ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2018; 9:2767.</a></li><li><a class="nounderline abstract_t">Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, et al. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Ben-Ami T, Revel-Vilk S, Brooks R, et al. Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency. J Pediatr 2016; 177:316.</a></li><li><a class="nounderline abstract_t">Hashem H, Egler R, Dalal J. Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. J Pediatr Hematol Oncol 2017; 39:e293.</a></li><li><a class="nounderline abstract_t">Sasa GS, Elghetany T, Bergstrom K, et al. Adenosine Deaminase 2 Deficiency as a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia. Blood 2015; 126:3615.</a></li><li><a class="nounderline abstract_t">Szvetnik EA, Klemann C, Hainmann I, et al. Diamond-Blackfan anemia phenotype caused by deficiency of adenosine deaminase 2. Blood 2017; 130:874.</a></li><li><a class="nounderline abstract_t">Sundin M, Marits P, Nierkens S, et al. "Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children. J Pediatr Hematol Oncol 2019; 41:155.</a></li><li><a class="nounderline abstract_t">Hsu AP, West RR, Calvo KR, et al. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. J Allergy Clin Immunol 2016; 138:628.</a></li><li><a class="nounderline abstract_t">Le Voyer T, Boutboul D, Ledoux-Pilon A, et al. Late-Onset EBV Susceptibility and Refractory Pure Red Cell Aplasia Revealing DADA2. J Clin Immunol 2020; 40:948.</a></li><li><a class="nounderline abstract_t">Staples E, Simeoni I, Stephens JC, et al. ADA2 deficiency complicated by EBV-driven lymphoproliferative disease. Clin Immunol 2020; 215:108443.</a></li><li><a class="nounderline abstract_t">Schena F, Penco F, Volpi S, et al. Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients. Eur J Immunol 2021; 51:206.</a></li><li><a class="nounderline abstract_t">Yap JY, Moens L, Lin MW, et al. Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency. J Clin Immunol 2021; 41:1915.</a></li><li><a class="nounderline abstract_t">Claassen D, Boals M, Bowling KM, et al. Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia. Cold Spring Harb Mol Case Stud 2018; 4.</a></li><li><a class="nounderline abstract_t">Muraoka T, Katsuramaki T, Shiraishi H, Yokoyama MM. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. Anal Biochem 1990; 187:268.</a></li><li><a class="nounderline abstract_t">Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem 1992; 38:1322.</a></li><li><a class="nounderline abstract_t">Samanta D, Cobb S, Arya K. Sneddon Syndrome: A Comprehensive Overview. J Stroke Cerebrovasc Dis 2019; 28:2098.</a></li><li><a class="nounderline abstract_t">Santo GC, Baldeiras I, Guerreiro R, et al. Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause. Cerebrovasc Dis 2018; 46:257.</a></li><li><a class="nounderline abstract_t">Burillo-Sanz S, Montes-Cano MA, García-Lozano JR, et al. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach. Sci Rep 2017; 7:8453.</a></li><li><a class="nounderline abstract_t">van Well GTJ, Kant B, van Nistelrooij A, et al. Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A&gt;G splice site mutation. Clin Exp Rheumatol 2019; 37 Suppl 121:142.</a></li><li><a class="nounderline abstract_t">Sharma A, Naidu GSRSNK, Chattopadhyay A, et al. Novel CECR1 gene mutations causing deficiency of adenosine deaminase 2, mimicking antiphospholipid syndrome. Rheumatology (Oxford) 2019; 58:181.</a></li><li><a class="nounderline abstract_t">Cooray S, Omyinmi E, Hong Y, et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology (Oxford) 2021; 60:4373.</a></li><li><a class="nounderline abstract_t">Lee PY, Huang Y, Zhou Q, et al. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol 2018; 142:1363.</a></li><li><a class="nounderline abstract_t">Liu L, Wang W, Wang Y, et al. A Chinese DADA2 patient: report of two novel mutations and successful HSCT. Immunogenetics 2019; 71:299.</a></li><li><a class="nounderline abstract_t">Rama M, Duflos C, Melki I, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet 2018; 26:960.</a></li><li><a class="nounderline abstract_t">Hashem H, Vatsayan A, Gupta A, et al. Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2. Bone Marrow Transplant 2017; 52:1575.</a></li><li><a class="nounderline abstract_t">Hashem H, Bucciol G, Ozen S, et al. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. J Clin Immunol 2021; 41:1633.</a></li><li><a class="nounderline abstract_t">Sahin S, Adrovic A, Kasapcopur O. A monogenic autoinflammatory disease with fatal vasculitis: deficiency of adenosine deaminase 2. Curr Opin Rheumatol 2020; 32:3.</a></li></ol></div><div id="topicVersionRevision">Topic 132472 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552284" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Early-onset stroke and vasculopathy associated with mutations in ADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552285" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26233953" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867732" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34004258" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522451" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021335" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30503522" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Genetic Landscape of Diamond-Blackfan Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32276138" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059682" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32638197" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945408" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353490" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Deficiency of adenosine deaminase 2: Is it an elephant after all?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892503" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31043544" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28974505" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28983775" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054602" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Response to: 'Total adenosine deaminase highly correlated with adenosine deaminase 2 activity in serum' by Gao et al.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15926889" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453107" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31015188" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995379" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment Strategies for Deficiency of Adenosine Deaminase 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30647181" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830446" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33529688" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32743071" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cellular sensing of extracellular purine nucleosides triggers an innate IFN-βresponse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : ADA2 is a lysosomal DNase regulating the type-I interferon response</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26922074" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28493328" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30406060" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29951947" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676630" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Deficiency of adenosine deaminase 2 diagnosed at 65 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29391253" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ADA2 deficiency: Clonal lymphoproliferation in a subset of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31291964" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024309" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34571400" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29271561" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692987" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30139808" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514238" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28230570" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adenosine Deaminase 2 Deficiency as a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diamond-Blackfan anemia phenotype caused by deficiency of adenosine deaminase 2</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29620681" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : "Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27130863" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32643137" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Late-Onset EBV Susceptibility and Refractory Pure Red Cell Aplasia Revealing DADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353633" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ADA2 deficiency complicated by EBV-driven lymphoproliferative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707604" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34657246" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559313" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382828" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623598" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Serum adenosine deaminase: isoenzymes and diagnostic application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160219" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sneddon Syndrome: A Comprehensive Overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30645994" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814775" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A Next Generation Sequencing approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856934" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A&gt;G splice site mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165497" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Novel CECR1 gene mutations causing deficiency of adenosine deaminase 2, mimicking antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33420503" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936104" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30610243" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A Chinese DADA2 patient: report of two novel mutations and successful HSCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29681619" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28805790" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34324127" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599797" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A monogenic autoinflammatory disease with fatal vasculitis: deficiency of adenosine deaminase 2.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
